Do you have the same question? Follow this Question
Oct 17, 2025 - 04:37 AM
We’ve provided several answers to questions related to Stelara (Ustekinumab) , see some other helpful Q&A related to this product.
Question: What is the ChEBI code for this medication?
Answer: The ChEBI code is CHEBI:955786. ChEBI codes are used in biochemical databases to uniquely identify substances.
Question: What is the MedlinePlus code for this medication?
Answer: The MedlinePlus code is a609032. MedlinePlus codes help patients and providers access reliable medical information about the medication.
Question: What is the PubChem CID for this medication?
Answer: The PubChem CID is 16134774. PubChem CID is a unique identifier used in scientific research databases, aiding professionals in finding detailed information about the compound.
Question: Is this medication approved by regulatory agencies?
Answer: Yes, it is licensed by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency). Regulatory approval demonstrates the medication’s safety and efficacy have been thoroughly evaluated.
Question: What are the brand names for this medication?
Answer: The medication is marketed under the brand name Stelara. Recognizing the brand name helps ensure you receive the correct medication at the pharmacy.
Question: What is the chemical name of the active ingredient?
Answer: The chemical name is ustekinumab. Knowing the chemical name can be helpful for understanding the active component when comparing medications or discussing treatment options.
Question: What are the inactive ingredients in the single-dose vial?
Answer: Inactive ingredients in the single-dose vial include L-histidine, L-histidine hydrochloride monohydrate, Polysorbate 80, and sucrose. These ingredients support the proper formulation and preservation of the medication.
Question: What are the inactive ingredients in the prefilled syringe?
Answer: Inactive ingredients in the prefilled syringe include L-histidine, L-histidine monohydrochloride monohydrate, Polysorbate 80, and sucrose. Inactive ingredients help maintain the stability and effectiveness of the medication.
Question: What conditions is this medication used to treat?
Answer: It is used to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This broad coverage means it can help people with several different autoimmune and inflammatory conditions.
Question: Can children use this medication?
Answer: Yes, pediatric patients who are at least 6 years old can use it for moderate to severe plaque psoriasis and active psoriatic arthritis. Availability for pediatric patients is valuable for families seeking effective treatments for children with these conditions.
Question: What is the protein binding property of this medication?
Answer: Protein binding is not applicable because this is a monoclonal antibody. Monoclonal antibodies function differently from typical drugs, which can be an advantage in targeting specific disease pathways.
Question: What is the legal status of this medication?
Answer: This medication is available by prescription only (Rx). Prescription-only status ensures that a healthcare provider evaluates whether this medication is appropriate for you, enhancing safety.
Question: What is the route of administration for this medication?
Answer: This medication can be administered subcutaneously (under the skin) and intravenously (IV, into a vein). Multiple administration routes provide flexibility for patients and healthcare providers based on individual needs.
Question: What is the bioavailability of this medication when given subcutaneously?
Answer: The bioavailability is 57.2% when administered subcutaneously. Bioavailability indicates how much of the drug enters the bloodstream, affecting how effective the treatment will be for the patient.
Question: What is the elimination half-life of this medication?
Answer: The elimination half-life ranges from 15 to 32 days. A longer half-life means the medication stays in your system for a significant period, allowing for less frequent dosing, which can be more convenient for patients.
Question: What is the chemical formula of ustekinumab?
Answer: The chemical formula is C6484H10004N1732O2020S42. Knowing the formula is valuable for healthcare professionals and researchers to understand the structure and composition of the medication.
Question: What strength is available in the single-dose vials?
Answer: The single-dose vials are available in 45 mg/0.5 mL. This provides an option for those who may require a specific dosage or prefer vials over prefilled syringes.
Question: What are the available strengths of the prefilled syringes?
Answer: The prefilled syringes are available in strengths of 45 mg/0.5 mL and 90 mg/mL. Having multiple strengths allows for dosing flexibility, which helps healthcare providers tailor treatment to each patient’s needs.
Question: What is the active ingredient in this medication?
Answer: The active ingredient is ustekinumab. Ustekinumab is a monoclonal antibody, which is a type of protein designed to target specific parts of your immune system, making it a valuable option for those with autoimmune conditions.
